• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Indswftlab Share Price

    Ind-Swift Laboratories Share PriceInd-Swift Laboratories

    Small Cap 7.8k Result
    ₹91.5
    1.15 (1.27%)
    As on 10 December, 2023 | 12:35 BSE: 532305 NSE: INDSWFTLABISIN: INE915B01019

    Ind-Swift Laboratories Performance

    Day Range

    • Low 89.50
    • High 92.50
    ₹ 91.5

    52 Week Range

    • Low 53.95
    • High 123.40
    ₹ 91.5
    • Open Price91.00
    • Previous Close90.35
    • Volume198379

    Start SIP in Ind-Swift Laboratories

    Start SIP

    Ind-Swift Laboratories Share Price

    • Over 1 Month -3.99%
    • Over 3 Month -1.24%
    • Over 6 Month 30.43%
    • Over 1 Year 27.44%

    Ind-Swift Laboratories Key Statistics

    P/E Ratio 10.3
    PEG Ratio 0
    Market Cap Cr 541
    Price to Book Ratio 1.1
    EPS 9.5
    Dividend 0
    Relative Strength Index 47.96
    Money Flow Index 37.43
    MACD Signal 0.26
    Average True Range 2.95

    Ind-Swift Laboratories Investment Rating

    • Master Rating:

    • Ind-Swift Labs. (Nse) has an operating revenue of Rs. 1,216.98 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 7% is okay, ROE of 9% is fair but needs improvement. The company has a high debt to equity of 151%, which can be a reason to worry. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 13% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 36 which is a POOR score indicating inconsistency in earnings, a RS Rating of 54 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 68 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Ind-Swift Laboratories Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 270299290302288272276
    Operating Expenses Qtr Cr 207239234246231219241
    Operating Profit Qtr Cr 63605656575335
    Depreciation Qtr Cr 1314915161682
    Interest Qtr Cr 21202222242423
    Tax Qtr Cr 61439-30014
    Net Profit Qtr Cr 3017-31292420-63
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 1,1851,030
    Operating Expenses Annual Cr 930794
    Operating Profit Annual in Cr 222194
    Depreciation Cr 57131
    Interest Annual Cr 9296
    Tax Annual Cr 3714
    Net Profit Annual Cr 42-6
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 136136
    Cash from Investing Activity Annual Cr 33
    Cash from Financing Annual Activity Cr -140-140
    Net Cash Flow Annual Cr -1
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 675633
    Fixed Assets Annual Cr 595640
    Total Non Current Assets Annual Cr 714804
    Total Current Assets Annual Cr 1,074999
    Total Assets Annual Cr 1,7881,803
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 113106
    ROE Annual % 9-1
    ROCE Annual % 147
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2224
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 290310304313310280307
    Operating Expenses Qtr Cr 224250240259251227270
    Operating Profit Qtr Cr 66606554595337
    Depreciation Qtr Cr 1314915161682
    Interest Qtr Cr 21202222242423
    Tax Qtr Cr 71441-31014
    Net Profit Qtr Cr 3217-24272520-61
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 1,2411,081
    Operating Expenses Annual Cr 978842
    Operating Profit Annual in Cr 229196
    Depreciation Cr 57131
    Interest Annual Cr 9296
    Tax Annual Cr 3915
    Net Profit Annual Cr 48-2
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 195150
    Cash from Investing Activity Annual Cr -135
    Cash from Financing Annual Activity Cr -186-141
    Net Cash Flow Annual Cr -414
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 682601
    Fixed Assets Annual Cr 595641
    Total Non Current Assets Annual Cr 660724
    Total Current Assets Annual Cr 1,1651,076
    Total Assets Annual Cr 1,8241,801
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 114100
    ROE Annual % 10-1
    ROCE Annual % 147
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2223
    Invest in Ind-Swift Laboratories

    Ind-Swift Laboratories Technicals

    EMA & SMA

    Current Price
    ₹91.5
    1.15 (1.27%)
    pointer
    • Bullish Moving Average
    • ___
    • 7
    • Bearish Moving Average
    • ___
    • 9
    • 20 Day
    • ₹92.00
    • 50 Day
    • ₹91.67
    • 100 Day
    • ₹89.45
    • 200 Day
    • ₹83.57
    • 20 Day
    • ₹92.99
    • 50 Day
    • ₹91.10
    • 100 Day
    • ₹92.56
    • 200 Day
    • ₹80.79

    Ind-Swift Laboratories Resistance and Support

    PIVOT
    ₹91.17
    Resistance
    First Resistance 92.83
    Second Resistance 94.17
    Third Resistance 95.83
    RSI 47.96
    MFI 37.43
    MACD Single Line 0.26
    MACD -0.10
    Support
    First Resistance 89.83
    Second Resistance 88.17
    Third Resistance 86.83

    Ind-Swift Laboratories Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 224,298 13,500,497 60.19
    Week 121,235 8,168,841 67.38
    1 Month 147,231 8,742,582 59.38
    6 Month 421,366 19,492,409 46.26

    Ind-Swift Laboratories Result Highlights

    Ind-Swift Laboratories Synopsis

    NSE-Medical-Generic Drugs

    Ind-Swift Laboratori is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1151.96 Cr. and Equity Capital is Rs. 59.81 Cr. for the Year ended 31/03/2023. Ind-Swift Laboratories Ltd. is a Public Limited Listed company incorporated on 04/01/1995 and has its registered office in the State of Chandigarh, India. Company’s Corporate Identification Number(CIN) is L24232CH1995PLC015553 and registration number is 015553.
    Market Cap 541
    Sales 1,162
    Shares in Float 3.43
    No of funds 5
    Yield
    Book Value 1.11
    U/D Vol ratio 1
    LTDebt / Equity 151
    Alpha 0.1
    Beta 0.88

    Ind-Swift Laboratories

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 42%42%42%42%
    Foreign Portfolio Investors 0.17%0.08%0.04%
    Individual Investors 28.77%29.21%29.08%28.97%
    Others 29.06%28.71%28.92%28.99%

    Ind-Swift Laboratories Management

    Name Designation
    Mr. N R Munjal Chairman & Managing Director
    Mr. Himanshu Jain Joint Managing Director
    Mr. Rishav Mehta Executive Director
    Mr. Sahil Munjal Executive Director
    Dr. Ashwani Kumar Vig Independent Director
    Mr. Rajinder Kumar Gupta Independent Director
    Mr. S P Sharma Independent Director
    Ms. Neerja Chathley Independent Woman Director

    Ind-Swift Laboratories Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Ind-Swift Laboratories Corporate Action

    Date Purpose Remarks
    2023-11-07 Quarterly Results
    2023-08-09 Quarterly Results
    2023-05-29 Audited Results
    2023-02-14 Quarterly Results
    2022-11-08 Quarterly Results

    Ind-Swift Laboratories MF Shareholding

    Name Amount(cr)
    Motilal Oswal S&P BSE Healthcare ETF 8

    Ind-Swift Laboratories FAQs

    What is Share Price of Ind-Swift Laboratories ?

    Ind-Swift Laboratories share price is ₹91 As on 10 December, 2023 | 12:21

    What is the Market Cap of Ind-Swift Laboratories ?

    The Market Cap of Ind-Swift Laboratories is ₹540.6 Cr As on 10 December, 2023 | 12:21

    What is the P/E ratio of Ind-Swift Laboratories ?

    The P/E ratio of Ind-Swift Laboratories is 10.3 As on 10 December, 2023 | 12:21

    What is the PB ratio of Ind-Swift Laboratories ?

    The PB ratio of Ind-Swift Laboratories is 1.1 As on 10 December, 2023 | 12:21

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.